JP2019517485A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517485A5 JP2019517485A5 JP2018562232A JP2018562232A JP2019517485A5 JP 2019517485 A5 JP2019517485 A5 JP 2019517485A5 JP 2018562232 A JP2018562232 A JP 2018562232A JP 2018562232 A JP2018562232 A JP 2018562232A JP 2019517485 A5 JP2019517485 A5 JP 2019517485A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- fluoro
- weeks
- administered
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 5
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical group C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 5
- 229960001507 ibrutinib Drugs 0.000 claims 5
- 229960004641 rituximab Drugs 0.000 claims 5
- 229940124291 BTK inhibitor Drugs 0.000 claims 4
- 206010066476 Haematological malignancy Diseases 0.000 claims 4
- 229940124639 Selective inhibitor Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 108091008875 B cell receptors Proteins 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 claims 1
- NWKPMPRXJGMTKQ-DIAVIDTQSA-N 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-2,3-dihydroxypropan-1-one Chemical compound NC1=C2C(=NC=N1)N(N=C2C2=CC=C(C=C2)OC2=CC=CC=C2)[C@H]2CN(CCC2)C(C(CO)O)=O NWKPMPRXJGMTKQ-DIAVIDTQSA-N 0.000 claims 1
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 claims 1
- IUVCFHHAEHNCFT-UHFFFAOYSA-N 2-[1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical group C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1C(C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-UHFFFAOYSA-N 0.000 claims 1
- SMOPKEHQPPXRSH-UHFFFAOYSA-N 2-methyl-n-[2-[3-[[2-(prop-2-enoylamino)acetyl]amino]anilino]pyrimidin-5-yl]-5-[[3-(trifluoromethyl)benzoyl]amino]benzamide Chemical compound C1=C(C(=O)NC=2C=NC(NC=3C=C(NC(=O)CNC(=O)C=C)C=CC=3)=NC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 SMOPKEHQPPXRSH-UHFFFAOYSA-N 0.000 claims 1
- VVLHQJDAUIPZFH-UHFFFAOYSA-N 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC=3N=C(NC=4C=C(NC(=O)C=C)C=CC=4)C(F)=CN=3)=CC=2)=C1 VVLHQJDAUIPZFH-UHFFFAOYSA-N 0.000 claims 1
- KSUDUUBCXJUFRL-SFHVURJKSA-N 6-amino-7-(4-phenoxyphenyl)-9-[(3s)-1-prop-2-enoylpiperidin-3-yl]purin-8-one Chemical compound O=C1N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C=2C(N)=NC=NC=2N1[C@H]1CCCN(C(=O)C=C)C1 KSUDUUBCXJUFRL-SFHVURJKSA-N 0.000 claims 1
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 claims 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- -1 INCB-50465 Chemical compound 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZHXNIYGJAOPMSO-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)(C)C)C=C1 ZHXNIYGJAOPMSO-UHFFFAOYSA-N 0.000 claims 1
- 208000025316 Richter syndrome Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 230000025084 cell cycle arrest Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 claims 1
- CDOOFZZILLRUQH-GDLZYMKVSA-N n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)[C@H]1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-GDLZYMKVSA-N 0.000 claims 1
- DQPJVNQWPBLBAB-UHFFFAOYSA-N n-[5-[[3-(4-acetylpiperazine-1-carbonyl)-4,5-dimethylphenyl]methylsulfanyl]-1,3-thiazol-2-yl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide Chemical compound C1=CC(CNC(C)C(C)(C)C)=CC=C1C(=O)NC(S1)=NC=C1SCC1=CC(C)=C(C)C(C(=O)N2CCN(CC2)C(C)=O)=C1 DQPJVNQWPBLBAB-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342822P | 2016-05-27 | 2016-05-27 | |
| US62/342,822 | 2016-05-27 | ||
| PCT/US2017/034855 WO2017205843A1 (en) | 2016-05-27 | 2017-05-26 | Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517485A JP2019517485A (ja) | 2019-06-24 |
| JP2019517485A5 true JP2019517485A5 (OSRAM) | 2020-07-02 |
Family
ID=60412660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562232A Pending JP2019517485A (ja) | 2016-05-27 | 2017-05-26 | Ｂ細胞増殖性障害を治療するための抗ｃｄ２０抗体、ｐ１３キナーゼ−デルタ選択的阻害剤およびｂｔｋ阻害剤の組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10966977B2 (OSRAM) |
| EP (1) | EP3463318A4 (OSRAM) |
| JP (1) | JP2019517485A (OSRAM) |
| KR (1) | KR20190015351A (OSRAM) |
| CN (1) | CN109640964A (OSRAM) |
| AU (1) | AU2017268839A1 (OSRAM) |
| BR (1) | BR112018074238A2 (OSRAM) |
| CA (1) | CA3024123A1 (OSRAM) |
| CL (1) | CL2018003349A1 (OSRAM) |
| EA (1) | EA201892284A1 (OSRAM) |
| IL (1) | IL263239A (OSRAM) |
| MX (1) | MX2018014577A (OSRAM) |
| SG (1) | SG11201810333UA (OSRAM) |
| WO (1) | WO2017205843A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231207T1 (hr) | 2015-04-06 | 2024-01-19 | Janssen Pharmaceutica Nv | Pripravak koji sadrži ibrutinib |
| KR102436875B1 (ko) * | 2017-12-08 | 2022-08-26 | 주식회사 보령 | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 |
| EP3799603A4 (en) | 2018-05-11 | 2022-03-02 | Beam Therapeutics, Inc. | METHODS OF PATHOGENIC AMINO ACID SUBSTITUTION USING PROGRAMMABLE BASE EDITOR SYSTEMS |
| KR20250125432A (ko) | 2018-06-15 | 2025-08-21 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| KR20220035169A (ko) * | 2019-07-15 | 2022-03-21 | 존슨 맛쎄이 퍼블릭 리미티드 컴파니 | 비정질 움브랄리십 모노토실레이트 |
| US20220143026A1 (en) | 2020-11-12 | 2022-05-12 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| AU2022254689A1 (en) * | 2021-04-08 | 2023-11-16 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a her2 targeted antibody |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| AU8619698A (en) | 1997-07-25 | 1999-02-16 | Ban C. H. Tsui | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| US7663057B2 (en) | 2004-02-19 | 2010-02-16 | Nanosolar, Inc. | Solution-based fabrication of photovoltaic cell |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| US8543180B2 (en) | 2006-05-03 | 2013-09-24 | Covidien Lp | Method and apparatus for total hemoglobin measurement |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP3444242A3 (en) | 2009-11-05 | 2019-03-20 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
| HRP20171610T1 (hr) | 2012-07-04 | 2018-03-23 | Rhizen Pharmaceuticals S.A. | Selektivni inhibitori pi3k delta |
| EP3756686A1 (en) * | 2012-11-02 | 2020-12-30 | TG Therapeutics Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| EP3119910A4 (en) | 2014-03-20 | 2018-02-21 | Pharmacyclics LLC | Phospholipase c gamma 2 and resistance associated mutations |
| HUE054916T2 (hu) | 2014-05-27 | 2021-10-28 | Rhizen Pharmaceuticals S A | PI3K delta szelektív gátló kristályos toszilát-sója gyógyszerkészítményekben történõ alkalmazásra |
| JP2017523207A (ja) | 2014-08-08 | 2017-08-17 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害薬の組み合わせ及びそれらの使用 |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
-
2017
- 2017-05-26 CN CN201780032933.0A patent/CN109640964A/zh active Pending
- 2017-05-26 WO PCT/US2017/034855 patent/WO2017205843A1/en not_active Ceased
- 2017-05-26 AU AU2017268839A patent/AU2017268839A1/en not_active Abandoned
- 2017-05-26 JP JP2018562232A patent/JP2019517485A/ja active Pending
- 2017-05-26 US US16/304,590 patent/US10966977B2/en not_active Expired - Fee Related
- 2017-05-26 CA CA3024123A patent/CA3024123A1/en not_active Abandoned
- 2017-05-26 KR KR1020187037436A patent/KR20190015351A/ko not_active Ceased
- 2017-05-26 SG SG11201810333UA patent/SG11201810333UA/en unknown
- 2017-05-26 EP EP17803731.3A patent/EP3463318A4/en not_active Withdrawn
- 2017-05-26 EA EA201892284A patent/EA201892284A1/ru unknown
- 2017-05-26 MX MX2018014577A patent/MX2018014577A/es unknown
- 2017-05-26 BR BR112018074238-4A patent/BR112018074238A2/pt not_active Application Discontinuation
-
2018
- 2018-11-22 IL IL263239A patent/IL263239A/en unknown
- 2018-11-23 CL CL2018003349A patent/CL2018003349A1/es unknown
-
2021
- 2021-02-12 US US17/175,184 patent/US20210169878A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517485A5 (OSRAM) | ||
| JP2019506403A5 (OSRAM) | ||
| US20240009196A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2018524347A5 (OSRAM) | ||
| JP2014533279A5 (OSRAM) | ||
| US12194095B2 (en) | Combinations and uses thereof | |
| JP2017506227A5 (OSRAM) | ||
| JP2017528462A5 (OSRAM) | ||
| JP2015532292A5 (OSRAM) | ||
| JP2019526595A5 (OSRAM) | ||
| JP2022137089A (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| JP2010512407A5 (OSRAM) | ||
| CN103732252B (zh) | 使用抗cd‑19抗体和氮芥的联合治疗 | |
| JP2020523384A5 (OSRAM) | ||
| JP2018524361A5 (OSRAM) | ||
| JP2015516980A5 (OSRAM) | ||
| JP2010525046A (ja) | 血液系腫瘍の治療のための方法 | |
| RU2013127115A (ru) | Комбинированная терапия при в-клеточных лимфомах | |
| US20110129467A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| Bofill et al. | American Society of Hematology (ASH)-56Th Annual Meeting and Exposition-San Francisco, California, USA, December 6-9, 2014 |